SUBSCRIBE
SUBSCRIBE
News   Drug Development

AVANIR Pharmaceuticals Announces Last Patient Enrolled In Neuropathic Pain Phase III Trial With Zenvia

November 15, 2006 | 
1 min read
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.
Clinical research Phase 3
MORE ON THIS TOPIC
cloud with rain of coins on blue background. minimal concept of investment, success and cryptocurrencies. 3d rendering
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
March 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
March 3, 2026
 · 
1 min read
 · 
BioSpace Insights
Dream Birds Flying Away, the birds flying out of a bird an open cage, the birds released from a cage, freedom concept. birds set free vector illustration.
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
 · 
3 min read
 · 
Heather McKenzie